{"text": "amgen's imlygic shows treatment effect in metastatic melanoma patients in mid-stage study URL $amgn $bmy #sitifatimah \u00a1\u00ad"}
{"text": "amgen's imlygic shows treatment effect in metastatic melanoma patients in mid-stage study URL $amgn $bmy"}
{"text": "amgen's imlygic shows treatment effect in metastatic melanoma patients in mid-stage study URL $amgn $bmy"}
{"text": "bristol-myers teams up with qiagen to develop gene expression profiles as prognostic aids with i-o drugs URL $bmy $qge\u00a1\u00ad"}
{"text": "$bmy, $qgen ink ngs technology deal to develop gene expression profiles for immuno-oncology therapies URL"}
{"text": "bristol-myers teams up with qiagen to develop gene expression profiles as prognostic aids with i-o drugs URL $bmy $qgen"}
{"text": "bristol-myers teams up with qiagen to develop gene expression profiles as prognostic aids with i-o drugs URL $bmy $qgen"}
{"text": "#asco17 $sgen booth with no crazy display? has $bmy and #nivol eaten into #adcetris that much that they have no $$$? URL"}
{"text": "$bmy nice set-up.  $ibb &amp; $xbi confirming."}
{"text": "$bmy announces interim data from checkmate -142, a phase 2, multi-cohort trial evaluating opdivo (nivolumab) monot\u00a1\u00ad URL"}
{"text": "rt AT_USER #asco2017 can someone post the $bmy lag3 pd-1 combo poster. thanks."}
{"text": "#asco2017 can someone post the $bmy lag3 pd-1 combo poster. thanks."}
{"text": "rt AT_USER $bmy poster: lag-3+pd1 = 13% orr in melanoma pts who have progressed on pd1 and ctla4 #asco17"}
{"text": "rt AT_USER $bmy poster: lag-3+pd1 = 13% orr in melanoma pts who have progressed on pd1 and ctla4 #asco17"}
{"text": "33 stocks for june 2017 URL $a $acad $adsk $aeis $agu $aig $amkr $antm $apo $bac $bco $bmy $burl $bx $byd $cbt $cdw"}
{"text": "$bmy poster: lag-3+pd1 = 13% orr in melanoma pts who have progressed on pd1 and ctla4 #asco17"}
{"text": "they key on the $bmy lag3 data is the high lag3 expressers. 5 of 6 responses in those 22 patients. #asco2017"}
{"text": "bristol-myers announces data from checkmate -142 URL $bmy #sitifatimah #malaysia #financialplanning"}
{"text": "bristol-myers announces data from checkmate -142 URL $bmy"}
{"text": "bristol-myers announces data from checkmate -142 URL $bmy"}
{"text": "rt AT_USER $mrk $incy $bmy URL"}
{"text": "rt AT_USER $bmy lag-3 orr was 12.5% in patients who were r/r to opdivo. 20% in patients who expressed &gt; 1% cells lag-3+. URL"}
{"text": "rt AT_USER opdivo+yervoy only 5% difference  in os vs opdivo in cm-012 eeeek. moreover patients that d/c combo continued benefit\u00a1\u00ad"}
{"text": "$mrk $incy $bmy URL"}
{"text": "#bristolmyerssquibb bristol-myers squibb and qiagen sign agreement for use of ngs technology... read more: URL $bmy"}
{"text": "#bristolmyerssquibb bristol-myers squibb and qiagen sign agreement for use of ngs technology... read more: URL $bmy"}
{"text": "nice piece of news on $qgen / $bmy collaboration. qiagen is the 3rd largest #vssporte #europeanbiotech position URL"}
{"text": "rt AT_USER $bmy $qgen sign agreement for use of ngs technology to develop gene expression profiles for i/o therapies URL"}
{"text": "rt AT_USER $bmy $qgen sign agreement for use of ngs technology to develop gene expression profiles for i/o therapies URL"}
{"text": "3 things in biotech you should learn today: june 3, 2017 $adro $bmy $nlnk $nvs $sgen URL URL"}
{"text": "3 things in biotech you should learn today: june 3, 2017 URL $adro $bmy $nlnk $nvs $sgen check out ticker symbol $dcsa\u00a1\u00ad"}
{"text": "3 things in biotech you should learn today: june 3, 2017 URL $adro $bmy $nlnk $nvs $sgen omg-stock symbol dcsa www.doc\u00a1\u00ad"}
{"text": "rt AT_USER $bmy $qgen sign agreement for use of ngs technology to develop gene expression profiles for i/o therapies URL"}
{"text": "$bmy $qgen sign agreement for use of ngs technology to develop gene expression profiles for i/o therapies URL"}
{"text": "rt AT_USER jpm #asco17 initial pd-1 combo takeaways $bmy $azn $mrk we are attending asco this weekend and wanted to (cont) URL"}
{"text": "3 things in biotech you should learn today: june 3, 2017 URL $adro $bmy $nlnk $nvs $sgen"}
{"text": "jpm #asco17 initial pd-1 combo takeaways $bmy $azn $mrk we are attending asco this weekend and wanted to (cont) URL"}
{"text": "rt AT_USER dcvax gives 2 marching orders 1. shift into attack 2. assign what to attack.  precision strikes.  $nwbo #asco2017 $kite $ju\u00a1\u00ad"}
{"text": "$bmy #bristol-myers squibb co. bristol-myers squibb and qiagen sign agreement for use of ngs technology to...\u00a1\u00ad URL"}
{"text": "rt AT_USER opdivo+yervoy only 5% difference  in os vs opdivo in cm-012 eeeek. moreover patients that d/c combo continued benefit\u00a1\u00ad"}
{"text": "rt AT_USER dcvax gives 2 marching orders 1. shift into attack 2. assign what to attack.  precision strikes.  $nwbo #asco2017 $kite $ju\u00a1\u00ad"}
{"text": "#bristolmyerssquibb bristol-myers squibb and qiagen sign agreement for use of ngs technology... read more: URL $bmy"}
{"text": "#bristolmyerssquibb bristol-myers squibb and qiagen sign agreement for use of ngs technology... read more: URL $bmy"}
{"text": "#bristolmyerssquibb : and qiagen sign agreement for use of ngs technology to develop gene ex... read more: URL $bmy"}
{"text": "#bristolmyerssquibb : and qiagen sign agreement for use of ngs technology to develop gene ex... read more: URL $bmy"}
{"text": "$bmy $qgen  sign agreement for use of ngs technology to develop  gene expression profiles for immuno-oncology therapies     #asco17"}
{"text": "$bmy bristol-myers squibb and qiagen sign agreement for use of ngs technology to develop gene expression ... - URL"}
{"text": "#bristolmyerssquibb antilag3 bms986016 in combination with opdivo nivolumab showed activity ... read more: URL $bmy"}
{"text": "#bristolmyerssquibb : opdivo (nivolumab) in combination with yervoy (ipilimumab) demonstrate... read more: URL $bmy"}
{"text": "#bristolmyerssquibb : opdivo (nivolumab) in combination with yervoy (ipilimumab) demonstrate... read more: URL $bmy"}
{"text": "#bristolmyerssquibb opdivo nivolumab in combination with yervoy ipilimumab demonstrated prom... read more: URL $bmy"}
{"text": "#bristolmyerssquibb opdivo nivolumab in combination with yervoy ipilimumab demonstrated prom... read more: URL $bmy"}
{"text": "#bristolmyerssquibb opdivo (nivolumab) in combination with yervoy (ipilimumab) demonstrated ... read more: URL $bmy"}
{"text": "#bristolmyerssquibb opdivo (nivolumab) in combination with yervoy (ipilimumab) demonstrated ... read more: URL $bmy"}
{"text": "#bristolmyerssquibb antilag3 bms986016 in combination with opdivo nivolumab showed activity ... read more: URL $bmy"}
{"text": "#bristolmyerssquibb anti-lag-3 (bms-986016) in combination with opdivo (nivolumab) showed ac... read more: URL $bmy"}
{"text": "#bristolmyerssquibb anti-lag-3 (bms-986016) in combination with opdivo (nivolumab) showed ac... read more: URL $bmy"}
{"text": "rt AT_USER opdivo+yervoy only 5% difference  in os vs opdivo in cm-012 eeeek. moreover patients that d/c combo continued benefit\u00a1\u00ad"}
{"text": "rt AT_USER immune-oncology drug trials are getting crowded - bloomberg $incy $mrk $bmy #investing #trading #biotech #tomstruths URL"}
{"text": "immune-oncology drug trials are getting crowded - bloomberg $incy $mrk $bmy #investing #trading #biotech #tomstruths URL"}
{"text": "rt AT_USER opdivo+yervoy only 5% difference  in os vs opdivo in cm-012 eeeek. moreover patients that d/c combo continued benefit\u00a1\u00ad"}
{"text": "rt AT_USER AT_USER AT_USER well it's spinnier than the alternative explanation that their drug simply isn't as good $bmy"}
{"text": "rt AT_USER opdivo+yervoy only 5% difference  in os vs opdivo in cm-012 eeeek. moreover patients that d/c combo continued benefit\u00a1\u00ad"}
{"text": "and it's not the riskiest. nivo is #asco17 $mrk $bmy $rhhby URL"}
{"text": "rt AT_USER opdivo+yervoy only 5% difference  in os vs opdivo in cm-012 eeeek. moreover patients that d/c combo continued benefit\u00a1\u00ad"}
{"text": "rt AT_USER opdivo+yervoy only 5% difference  in os vs opdivo in cm-012 eeeek. moreover patients that d/c combo continued benefit\u00a1\u00ad"}
{"text": "#bristolmyerssquibb first ec approval for immuno-oncology drug in specific bladder cancer in... read more: URL $bmy"}
{"text": "#bristolmyerssquibb first ec approval for immuno-oncology drug in specific bladder cancer in... read more: URL $bmy"}
{"text": "rt AT_USER opdivo+yervoy only 5% difference  in os vs opdivo in cm-012 eeeek. moreover patients that d/c combo continued benefit\u00a1\u00ad"}
{"text": "rt AT_USER opdivo+yervoy only 5% difference  in os vs opdivo in cm-012 eeeek. moreover patients that d/c combo continued benefit\u00a1\u00ad"}
{"text": "rt AT_USER opdivo+yervoy only 5% difference  in os vs opdivo in cm-012 eeeek. moreover patients that d/c combo continued benefit\u00a1\u00ad"}
{"text": "industry pulse: r&amp;d spending in charts URL $celg $agn $gild $azn $bmy $sny $jnj"}
{"text": "rt AT_USER opdivo+yervoy only 5% difference  in os vs opdivo in cm-012 eeeek. moreover patients that d/c combo continued benefit\u00a1\u00ad"}
{"text": "$bmy opdivo (nivolumab) in combination with yervoy (ipilimumab) demonstrated promising activity in previo... - URL"}
{"text": "rt AT_USER opdivo+yervoy only 5% difference  in os vs opdivo in cm-012 eeeek. moreover patients that d/c combo continued benefit\u00a1\u00ad"}
{"text": "opdivo+yervoy only 5% difference  in os vs opdivo in cm-012 eeeek. moreover patients that d/c combo continued benef\u00a1\u00ad URL"}
{"text": "rt AT_USER $bmy lag-3 orr was 12.5% in patients who were r/r to opdivo. 20% in patients who expressed &gt; 1% cells lag-3+. URL"}
{"text": "rt AT_USER $bmy lag-3 orr was 12.5% in patients who were r/r to opdivo. 20% in patients who expressed &gt; 1% cells lag-3+. URL"}
{"text": "rt AT_USER $bmy lag-3 orr was 12.5% in patients who were r/r to opdivo. 20% in patients who expressed &gt; 1% cells lag-3+. URL"}
{"text": "rt AT_USER i love AT_USER 's call on $bmy. mas converging. i will be adding when trend line breaks on volume. could be vola\u00a1\u00ad"}
{"text": "rt AT_USER $bmy lag-3 orr was 12.5% in patients who were r/r to opdivo. 20% in patients who expressed &gt; 1% cells lag-3+. URL"}
{"text": "$bmy lag-3 orr was 12.5% in patients who were r/r to opdivo. 20% in patients who expressed &gt; 1% cells lag-3+. URL"}
{"text": "$bmy anti-lag-3 (bms-986016) in combination with opdivo (nivolumab) showed activity in patients with mela... - URL"}
{"text": "caprock group inc. lowers position in bristol-myers squibb co $bmy URL"}
{"text": "bristol-myers squibb co $bmy position lowered by nationwide fund advisors URL"}
{"text": "ferguson wellman capital management inc. lowers position in bristol-myers squibb co $bmy URL"}
{"text": "rt AT_USER dcvax gives 2 marching orders 1. shift into attack 2. assign what to attack.  precision strikes.  $nwbo #asco2017 $kite $ju\u00a1\u00ad"}
{"text": "#bristolmyerssquibb european commission approves bristol-myers squibb's opdivo (nivolumab) f... read more: URL $bmy"}
{"text": "#bristolmyerssquibb european commission approves bristol-myers squibb's opdivo (nivolumab) f... read more: URL $bmy"}
{"text": "#bristolmyerssquibb brief-european commission approves bristol-myers squibb's opdivo (nivolu... read more: URL $bmy"}
{"text": "#bristolmyerssquibb brief-european commission approves bristol-myers squibb's opdivo (nivolu... read more: URL $bmy"}
{"text": "#bristolmyerssquibb european commission approves bristolmyers squibbs opdivo nivolumab for p... read more: URL $bmy"}
{"text": "#bristolmyerssquibb european commission approves bristolmyers squibbs opdivo nivolumab for p... read more: URL $bmy"}
{"text": "rt AT_USER $dvax  very likely to land a partnership with $bmy or $mrk in melanoma"}
{"text": "plenty can go right for bristol-myers $bmy - wsj URL"}
{"text": "3,905 shares in bristol-myers squibb co $bmy acquired by boyd watterson asset management llc oh URL"}
{"text": "3,905 shares in bristol-myers squibb co $bmy acquired by boyd watterson asset management llc oh URL"}
{"text": "3,905 shares in bristol-myers squibb co $bmy acquired by boyd watterson asset management llc oh URL"}
{"text": "patriot wealth management inc. invests $3.98 million in bristol-myers squibb co $bmy URL"}
{"text": "ferguson wellman capital management inc. lowers position in bristol-myers squibb co $bmy URL"}
